Search

Your search keyword '"O'Rourke, Robert"' showing total 469 results
Start Over Author "O'Rourke, Robert" Publication Type Academic Journals
469 results on '"O'Rourke, Robert"'

2. Postbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study

Author

Berk, Paul D., Bessler, Marc, Daud, Amna, Lobdell, Harrison, IV, Mwelu, Jemela, Schrope, Beth, Ude, Akuezunkpa, Honohan, Jamie, Capasso, Michelle, Costa, Ricardo, Dakin, Greg, Ebel, Faith, Gagner, Michel, Hsieh, Jane, Pomp, Alfons, Strain, Gladys, Bowden, Rita, Chapman, William, Cundiff, Blair, Ball, Mallory, Cunningham, Emily, Dohm, Lynis, Pender, John, Pories, Walter, Barker, Jennifer, Howell, Michael, Garcia, Luis, Lancaster, Kathy, Lovaas, Erika, Mitchell, James E., Monson, Tim, Cassady, Chelsea, Coburn, Emily, Moher, Emily, Deveney, Clifford, Elder, Katherine, Greene, Stefanie, Purnell, Jonathan, O’Rourke, Robert, Sorenson, Chad, Wolfe, Bruce M., Patterson, Emma, Raum, William, VanDerWerff, Lisa, Kwiatkowski, Jason, Courcoulas, Anita P., Gourash, William, McCloskey, Carol A., Ramanathan, Ramesh, Kalarchian, Melissa, Marcus, Marsha, Shirley, Eleanor, Turo, Angela, Flum, David R., Dellinger, E. Patchen, Khandelwal, Saurabh, Stewart, Skye D., Cooley, Morgan M., Blissell, Rebecca, Miller, Megan J., Thirlby, Richard, Chang, Lily, Hunter, Jeffrey, Moonka, Ravi, Ng, Debbie, Belle, Steven H., King, Wendy C., Martin, Debbie, Mercurio, Rocco, Wahed, Abdus, Averbach, Frani, Horlick, Mary, Miles, Carolyn W., Staten, Myrlene A., Yanovski, Susan Z., Kleiner, David E., Fischer, Laura E., Fino, Nora, Elman, Miriam R., Pories, Walter J., Purnell, Jonathan Q., and Patti, Mary-Elizabeth

Published
2021
Full Text
View/download PDF

11. Matrix density regulates adipocyte phenotype.

Author

Ky, Alexander, McCoy, Atticus J., Flesher, Carmen G., Friend, Nicole E., Li, Jie, Akinleye, Kore, Patsalis, Christopher, Lumeng, Carey N., Putnam, Andrew J., and O'Rourke, Robert W.

Subjects
DENSITY matrices, FAT cells, ADIPOSE tissues, HUMAN phenotype, AEROBIC metabolism
Abstract

Alterations of the extracellular matrix contribute to adipose tissue dysfunction in metabolic disease. We studied the role of matrix density in regulating human adipocyte phenotype in a tunable hydrogel culture system. Lipid accumulation was maximal in intermediate hydrogel density of 5 weight %, relative to 3% and 10%. Adipogenesis and lipid and oxidative metabolic gene pathways were enriched in adipocytes in 5% relative to 3% hydrogels, while fibrotic gene pathways were enriched in 3% hydrogels. These data demonstrate that the intermediate density matrix promotes a more adipogenic, less fibrotic adipocyte phenotype geared towards increased lipid and aerobic metabolism. These observations contribute to a growing literature describing the role of matrix density in regulating adipose tissue function. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Adipose METTL14‐Elicited N6‐Methyladenosine Promotes Obesity, Insulin Resistance, and NAFLD Through Suppressing β Adrenergic Signaling and Lipolysis.

Author

Kang, Qianqian, Zhu, Xiaorong, Ren, Decheng, Ky, Alexander, MacDougald, Ormond A., O'Rourke, Robert W., and Rui, Liangyou

Subjects
LIPOLYSIS, INSULIN resistance, NON-alcoholic fatty liver disease, HIGH-fat diet, WHITE adipose tissue, SYMPATHETIC nervous system
Abstract

White adipose tissue (WAT) lipolysis releases free fatty acids as a key energy substance to support metabolism in fasting, cold exposure, and exercise. Atgl, in concert with Cgi‐58, catalyzes the first lipolytic reaction. The sympathetic nervous system (SNS) stimulates lipolysis via neurotransmitter norepinephrine that activates adipocyte β adrenergic receptors (Adrb1‐3). In obesity, adipose Adrb signaling and lipolysis are impaired, contributing to pathogenic WAT expansion; however, the underling mechanism remains poorly understood. Recent studies highlight importance of N6‐methyladenosine (m6A)‐based RNA modification in health and disease. METTL14 heterodimerizes with METTL3 to form an RNA methyltransferase complex that installs m6A in transcripts. Here, this work shows that adipose Mettl3 and Mettl14 are influenced by fasting, refeeding, and insulin, and are upregulated in high fat diet (HFD) induced obesity. Adipose Adrb2, Adrb3, Atgl, and Cgi‐58 transcript m6A contents are elevated in obesity. Mettl14 ablation decreases these transcripts' m6A contents and increases their translations and protein levels in adipocytes, thereby increasing Adrb signaling and lipolysis. Mice with adipocyte‐specific deletion of Mettl14 are resistant to HFD‐induced obesity, insulin resistance, glucose intolerance, and nonalcoholic fatty liver disease (NAFLD). These results unravel a METTL14/m6A/translation pathway governing Adrb signaling and lipolysis. METTL14/m6A‐based epitranscriptomic reprogramming impairs adipose Adrb signaling and lipolysis, promoting obesity, NAFLD, and metabolic disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Effectiveness of Percutaneous Coronary Intervention in Patients With Silent Myocardial Ischemia (Post Hoc Analysis of the COURAGE Trial)

Author

Gosselin, Gilbert, Teo, Koon K., Tanguay, Jean-Francois, Gokhale, Rohit, Hartigan, Pamela M., Maron, David J., Gupta, Vipul, Mancini, G.B. John, Bates, Eric R., Chaitman, Bernard R., Spertus, John A., Kostuk, William J., Dada, Marcin, Sedlis, Steven P., Berman, Daniel S., Shaw, Leslee J., O'Rourke, Robert A., Weintraub, William S., and Boden, William E.

Published
2012
Full Text
View/download PDF

21. Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial

Author

Maron, David J., Boden, William E., Spertus, John A., Hartigan, Pamela M., Mancini, G.B. John, Sedlis, Steven P., Kostuk, William J., Chaitman, Bernard R., Shaw, Leslee J., Berman, Daniel S., Dada, Marcin, Teo, Koon K., Weintraub, William S., and O'Rourke, Robert A.

Published
2011
Full Text
View/download PDF

22. Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial

Author

Acharjee, Subroto, Teo, Koon K., Jacobs, Alice K., Hartigan, Pamela M., Barn, Kulpreet, Gosselin, Gilbert, Tanguay, Jean-Francois, Maron, David J., Kostuk, William J., Chaitman, Bernard R., Mancini, John G.B., Spertus, John A., Dada, Marcin R., Bates, Eric R., Booth, David C., Weintraub, William S., O’Rourke, Robert A., and Boden, William E.

Published
2016
Full Text
View/download PDF

23. Lumican modulates adipocyte function in obesity-associated type 2 diabetes.

Author

Strieder-Barboza, Flesher, Carmen G., Geletka, Lynn M., Eichler, Tad, Akinleye, Olukemi, Ky, Alexander, Ehlers, Anne P., Lumeng, Carey N., and O'Rourke, Robert W.

Subjects
TYPE 2 diabetes, FAT cells, ADIPOSE tissues, INSULIN sensitivity, INSULIN resistance
Abstract

Obesity-associated type 2 diabetes (DM) leads to adipose tissue dysfunction. Lumican is a proteoglycan implicated in obesity, insulin resistance (IR), and adipocyte dysfunction. Using human visceral adipose tissue (VAT) from subjects with and without DM, we studied lumican effects on adipocyte function. Lumican was increased in VAT and adipocytes in DM. Lumican knockdown in adipocytes decreased lipolysis and improved adipogenesis and insulin sensitivity in VAT adipocytes in DM, while treatment with human recombinant lumican increased lipolysis and impaired insulin-sensitivity in an ERK-dependent manner. We demonstrate that lumican impairs adipocyte metabolism, partially via ERK signalling, and is a potential target for developing adipose tissue-targeted therapeutics in DM. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

28. Impact of an Initial Strategy of Medical Therapy Without Percutaneous Coronary Intervention in High-Risk Patients From the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial

Author

Maron, David J., Spertus, John A., Mancini, G.B. John, Hartigan, Pamela M., Sedlis, Steven P., Bates, Eric R., Kostuk, William J., Dada, Marcin, Berman, Daniel S., Shaw, Leslee J., Chaitman, Bernard R., Teo, Koon K., O'Rourke, Robert A., Weintraub, William S., and Boden, William E.

Published
2009
Full Text
View/download PDF

29. Impact of Optimal Medical Therapy With or Without Percutaneous Coronary Intervention on Long-Term Cardiovascular End Points in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)

Author

Boden, William E., O'Rourke, Robert A., Teo, Koon K., Maron, David J., Hartigan, Pamela M., Sedlis, Steven P., Dada, Marcin, Labedi, Mohammed, Spertus, John A., Kostuk, William J., Berman, Daniel S., Shaw, Leslee J., Chaitman, Bernard R., Mancini, G.B. John, and Weintraub, William S.

Published
2009
Full Text
View/download PDF

30. The EMPOWER Study: Randomized, Prospective, Double-Blind, Multicenter Trial of Vagal Blockade to Induce Weight Loss in Morbid Obesity

Author

Sarr, Michael G., Billington, Charles J., Brancatisano, Roy, Brancatisano, Anthony, Toouli, James, Kow, Lilian, Nguyen, Ninh T., Blackstone, Robin, Maher, James W., Shikora, Scott, Reeds, Dominic N., Eagon, J. Christopher, Wolfe, Bruce M., O’Rourke, Robert W., Fujioka, Ken, Takata, Mark, Swain, James M., Morton, John M., Ikramuddin, Sayeed, Schweitzer, Michael, Chand, Bipan, Rosenthal, Raul, and The EMPOWER Study Group

Published
2012
Full Text
View/download PDF

31. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons

Author

Bonow, Robert O., Carabello, Blase A., Chatterjee, Kanu, de Leon, Antonio C., Jr, Faxon, David P., Freed, Michael D., Gaasch, William H., Lytle, Bruce W., Nishimura, Rick A., O'Gara, Patrick T., O'Rourke, Robert A., Otto, Catherine M., Shah, Pravin M., and Shanewise, Jack S.

Published
2008
Full Text
View/download PDF

33. ACC/AHA 2008 Guideline Update on Valvular Heart Disease: Focused Update on Infective Endocarditis: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons

Author

Nishimura, Rick A., Carabello, Blase A., Faxon, David P., Freed, Michael D., Lytle, Bruce W., O'Gara, Patrick T., O'Rourke, Robert A., and Shah, Pravin M.

Published
2008
Full Text
View/download PDF

38. Effect of Reversible Intermittent Intra-abdominal Vagal Nerve Blockade on Morbid Obesity: The ReCharge Randomized Clinical Trial

Author

Ikramuddin, Sayeed, Blackstone, Robin P., Brancatisano, Anthony, Toouli, James, Shah, Sajani N., Wolfe, Bruce M., Fujioka, Ken, Maher, James W., Swain, James, Que, Florencia G., Morton, John M., Leslie, Daniel B., Brancatisano, Roy, Kow, Lilian, O’Rourke, Robert W., Deveney, Clifford, Takata, Mark, Miller, Christopher J., Knudson, Mark B., Tweden, Katherine S., Shikora, Scott A., Sarr, Michael G., and Billington, Charles J.

Published
2014
Full Text
View/download PDF

41. Guidelines for clinical use of cardiac radionuclide imaging: A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (committee on radionuclide imaging) — Developed in collaboration with the American Society of Nuclear Cardiology

Author

Ritchie, James L., Bateman, Timothy M., Bonow, Robert O., Crawford, Michael H., Gibbons, Raymond J., Hall, Robert J., O’Rourke, Robert A., Parisi, Alfred F., Verani, Mario S., Ritchie, James L., Cheitlin, Melvin D., Garson, Arthur, Lewis, Richard P., O’Rourke, Robert A., Ryan, Thomas J., Schlant, Robert C., and Winters, William L.

Published
1995
Full Text
View/download PDF

44. Effect of PCI on quality of life in patients with stable coronary disease

Author

Weintraub, William S., Spertus, John A., Kolm, Paul, Maron, David J., Zefeng Zhang, Jurkowitz, Claudine, Wei Zhang, Hartigan, Pamela M., Lewis, Cheryl, Veledar, Emir, Bowen, Jim, Dunbar, Sandra B., Deaton, Christi, Kaufman, Stanley, O'Rourke, Robert A., Goeree, Ron, Barnett, Paul G, Koon K. Teo, and Boden, William E.

Subjects
Coronary heart disease -- Risk factors, Coronary heart disease -- Care and treatment, Transluminal angioplasty -- Health aspects, Unstable angina -- Care and treatment
Abstract

The study examines if percutaneous coronary intervention.(PCI) provides an incremental benefit in quality of life over that offered by optimal medical therapy among patients with chronic coronary artery disease. Patients with stable angina in both treatment groups showed definite improvement in health status, whereas the PCI group showed small, but significant, incremental benefits that disappeared by 36 months.

Published
2008

46. Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424

Author

Shaw, Leslee J., Miranda-Peats, Romalisa, Slomka, Piotr, Friedman, John, Hayes, Sean W., Berman, Daniel S., Heller, Gary V., Dada, Marcin, Boden, William E., Casperson, Paul, O’Rourke, Robert A., Schwartz, Ronald, Weintraub, William S., Maron, David J., King, Spencer, Teo, Koon, and Hartigan, Pamela

Published
2006
Full Text
View/download PDF

48. Optimal medical therapy with or without PCI for stable coronary disease

Author

Boden, William E, O'Rourke Robert A, Teo, Koon K, Hartigan, Pamela M, Maron, David J., Koustuk, William J, Knudtson, Merril, Dada, Marcin, Casperson, Paul, Harris, Crystal L., Chaitman, Bernard R, Shaw, Leslee, Gosselin, Gilbert, Nawaz, Shah, Title, Lawrence M., Gau, Gerald, Blaustein, Alvin S, Booth, David C, Bates, Eric R, Spertus, John A., Berman, Daniel S, Mancini, G.B. John, and Weintraub, William S.

Subjects
Coronary heart disease -- Care and treatment, Angioplasty -- Usage, Cardiovascular diseases -- Risk factors
Abstract

Trials conducted reveal that percutaneous coronary intervention (PCI) in addition to optimal medical therapy does not reduce major cardiovascular events and risk of death in patients with stable coronary disease compared to optimal medical therapy alone.

Published
2007

50. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial

Author

Weintraub, William S., Barnett, Paul, Chen, Shuo, Hartigan, Pamela, Casperson, Paul, O'Rourke, Robert, Boden, William E., Lewis, Cheryl, Veledar, Emir, Becker, Edmund, Culler, Steven, Kolm, Paul, Mahoney, Elizabeth M., Dunbar, Sandra B., Deaton, Christi, O'Brien, Bernard, Goeree, Ron, Blackhouse, Gordon, Nease, Robert, Spertus, John, Kaufman, Stan, and Teo, Koon

Subjects
Coronary heart disease -- Care and treatment, Coronary heart disease -- Economic aspects, Coronary heart disease -- Research, Transluminal angioplasty -- Patient outcomes, Cost benefit analysis -- Research, Outcome and process assessment (Health Care) -- Economic aspects, Outcome and process assessment (Health Care) -- Research, Cost benefit analysis, Health
Published
2006

Catalog

Books, media, physical & digital resources
See catalog results